GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Debt-to-Equity

MaxCyte (LSE:MXCT) Debt-to-Equity : 0.08 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is MaxCyte Debt-to-Equity?

MaxCyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.61 Mil. MaxCyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £14.20 Mil. MaxCyte's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £183.41 Mil. MaxCyte's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MaxCyte's Debt-to-Equity or its related term are showing as below:

LSE:MXCT' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.98   Med: 0.15   Max: 0.99
Current: 0.08

During the past 12 years, the highest Debt-to-Equity Ratio of MaxCyte was 0.99. The lowest was -2.98. And the median was 0.15.

LSE:MXCT's Debt-to-Equity is ranked better than
71.79% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs LSE:MXCT: 0.08

MaxCyte Debt-to-Equity Historical Data

The historical data trend for MaxCyte's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Debt-to-Equity Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.21 0.02 0.06 0.08

MaxCyte Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.07 0.07 0.07 0.08

Competitive Comparison of MaxCyte's Debt-to-Equity

For the Medical Devices subindustry, MaxCyte's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MaxCyte's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MaxCyte's Debt-to-Equity falls into.



MaxCyte Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MaxCyte's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

MaxCyte's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MaxCyte  (LSE:MXCT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


MaxCyte Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MaxCyte's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte (LSE:MXCT) Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.